Dr. Shereef Elnahal, president and CEO of University Hospital in Newark, provides insight into potential development of a single Moderna vaccine that combines the coronavirus booster with the flu shot.
The Mayo Clinic is developing a breakthrough blood test that can detect more than 50 different types of cancer across all stages.
CDC ASKS TRAVELERS TO AVOID RUSSIA, OTHER COUNTRIES DUE TO HIGH COVID-19 RISK
The test, known as Galleri, was created in partnership with Menlo Park, California-based biotechnology and pharmaceutical company Grail.
Galleri, which is not covered by insurance, costs $949 and must be ordered by a licensed health care provider. (Grail)
Galleri looks for signals present in the blood stream that may be associated with cancer at the time of a blood draw. If a cancer signal is detected, Galleri will pinpoint where in the body the cancer is coming from to help health care providers determine the appropriate next steps for patient treatment.
Currently, recommended cancer screenings in the U.S. only cover five different types of cancer and can only screen for one type at a time. According to Grail, 71% of cancer deaths are caused by cancers that are not commonly screened for.
CLICK HERE TO READ MORE ON FOX BUSINESS
Galleri, which is not covered by insurance, costs $949 and must be ordered by a licensed health care provider, such as a physician, nurse practitioner, or physician’s assistant. Grail says that Galleri currently has an 89% accuracy rate in correctly predicting cancer signal origins and estimates that approximately 1 out of every 200 people tested by Galleri receive a false positive result.
Results typically come about two weeks after the blood draw. Galleri is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older, and should be used in addition to other routine cancer screening tests, such as a colonoscopy or mammograms.
Grail is currently working to obtain full approval for Galleri from the Food and Drug Administration. A Mayo Clinic spokesperson declined to offer a timeline on when the test will be widely available to consumers.